ReviewPharmaceutics2020
Mesoporous Silica Nanoparticles for the Treatment of Complex Bone Diseases: Bone Cancer, Bone Infection and Osteoporosis.
Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 132 citations in OpenAlex.
- Surface-Engineered Phytochemical Nanomedicines for Postmenopausal Osteoporosis: Skeletal Targeting, Imaging-Supported Evaluation, and Therapeutic Performance.Pharmaceutics · 2026Review
- Bacteria-Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Curcumin-based smart responsive hydrogels: A controlled release system for bone defect regeneration.Regenerative therapy · 2026Review
- Targeting intratumoral Streptococcus mitis suppresses the progression of esophageal squamous cell carcinoma.Science China. Life sciences · 2026Article
- Smart biomaterials for skeletal aging repair and regeneration.Bone research · 2026Review
- Current strategies for improving osseointegration of mesoporous silica drug delivery systems: A scoping review protocol.PloS one · 2026Article
- Holistic regulation of the diabetic osteo-microenvironment via NIR-II nanocarriers with dual NO/pH responsiveness for enhanced bone regeneration.Bioactive materials · 2025Article
- In vivo antimicrobial activity of engineered mesoporous silica nanoparticles targeting intracellular mycobacteria.Nature communications · 2025Article
- Synthesis ofBMC chemistry · 2025Article
- Nano-based Theranostics Approach in the Management of Cancer: Review.Pharmaceutical nanotechnology · 2025Review
- Unwinding the Threads of Mesoporous Silica Nanoparticles as Cutting-edge for the Management of Inflammation: An Updated Review.Current pharmaceutical biotechnology · 2025Review
- Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management.Advanced healthcare materials · 2024Review
- Antibiofilm activity of mesoporous silica nanoparticles against the biofilm associated infections.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Porous Chitosan/Hydroxyapatite Composite Microspheres for Vancomycin Loading and Releasing.Pharmaceutics · 2024Article
- Advanced Antimicrobial and Anti-Infective Strategies to Manage Peri-Implant Infection: A Narrative Review.Dentistry journal · 2024Review
- Effect of Modified Bioceramic Mineral Trioxide Aggregate Cement with Mesoporous Nanoparticles on Human Gingival Fibroblasts.Current issues in molecular biology · 2024Article
- Innovative Vancomycin-Loaded Hydrogel-Based Systems - New Opportunities for the Antibiotic Therapy.International journal of nanomedicine · 2024Article
- Evaluation of the Ocular Safety of Hollow Mesoporous Organosilica Nanoparticles with Different Tetrasulfur Bond Content.International journal of nanomedicine · 2024Article
- Organically Modified Mesoporous Silica Nanoparticles against Bacterial Resistance.Chemistry of materials : a publication of the American Chemical Society · 2023Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Bone diseases, such as bone cancer, bone infection and osteoporosis, constitute a major issue for modern societies as a consequence of their progressive ageing. Even though these pathologies can be currently treated in the clinic, some of those treatments present drawbacks that may lead to severe complications. For instance, chemotherapy lacks great tumor tissue selectivity, affecting healthy and diseased tissues. In addition, the inappropriate use of antimicrobials is leading to the appearance of drug-resistant bacteria and persistent biofilms, rendering current antibiotics useless. Furthermore, current antiosteoporotic treatments present many side effects as a consequence of their poor bioavailability and the need to use higher doses. In view of the existing evidence, the encapsulation and selective delivery to the diseased tissues of the different therapeutic compounds seem highly convenient. In this sense, silica-based mesoporous nanoparticles offer great loading capacity within their pores, the possibility of modifying the surface to target the particles to the malignant areas and great biocompatibility. This manuscript is intended to be a comprehensive review of the available literature on complex bone diseases treated with silica-based mesoporous nanoparticles-the further development of which and eventual translation into the clinic could bring significant benefits for our future society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.